P1201-07

P1201-07 is an investigational small molecule drug candidate developed by Piramal Enterprises (formerly Nicholas Piramal India Ltd.) for the treatment of obesity and overweight. It was designed as an orally administered agent and progressed into early-stage clinical development. The compound was evaluated in a Phase I, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy overweight or obese adult volunteers. While the specific biological target has not been publicly disclosed, the drug was part of Piramal's metabolic disorders research pipeline during the late 2000s.